Psychiatric symptoms and disorders in phenylketonuria

Molecular Genetics and Metabolism

Volumn 99, Issue SUPPL., 2010, Pages

  Brumm, V L ^a   Bilder, D ^b   Waisbren, S E ^c  

^a University of Utah School of Medicine ^*  (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Phenylketonuria; Psychiatric outcome; Psychological outcome

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; GENERALIZED ANXIETY DISORDER; HUMAN; MENTAL DISEASE; METABOLIC REGULATION; PHENYLKETONURIA; PHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; SELF ESTEEM; SOCIAL COMPETENCE; SOCIAL ISOLATION; SOCIAL PSYCHOLOGY; SOCIAL STATUS;

EID: 72549113240     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.182     Document Type: Article

References (48)

1. Scriver C.R., and Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver C.R., Beaudet A.L., Valle D., and Sly W.S. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 1667-1724
2. Jervis G.A. Phenylpyruvic oligophrenia. Arch. Neurol. Psychiatry 38 (1937) 944
3. Jervis G.A. Phenylpyruvic oligophrenia (phenylketonuria). Res. Publ. Assoc. Res. Nerv. Ment. Dis. 33 (1954) 259-282
4. Paine R.S. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 20 (1957) 290-302
5. Huttenlocher P.R. The neuropathology of phenylketonuria: human and animal studies. Eur. J. Pediatr. 159 (2000) S102-S106
6. Moyle J.J., Fox A.M., Arthur M., Bynevelt M., and Burnett J.R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 17 (2007) 91-101
7. Brumm V.L., Azen C., Moats R., Stern A., Broomand C., and Nelson M. Neuropsychological outcome of subjects participating in the PKU Adult Collaborative Study: a preliminary review. J. Inherit. Metab. Dis. 27 (2004) 549-566
8. Surtees R., and Blau N. The neurochemistry of phenylketonuria. Eur. J. Pediatr. 159 (2000) S109-S113
9. Scarabino T., Popolizio T., Tosetti M., Montanaro D., Giannatempo G.M., Terlizzi R., Pollice S., Maiorana A., Maggialetti N., Carriero A., Leuzzi V., and Salvolini U. Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol. Med. 114 (2009) 461-474
10. Jones S.J., Turano G., Kriss A., Shawkat F., Kendall B., and Thompson A.J. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. J. Neurol. Neurosurg. Psychiatry 59 (1995) 260-265
11. Pardridge W.M., and Choi T.B. Neutral amino acid transport at the human blood-brain barrier. Fed. Proc. 45 (1986) 2073-2078
12. Guttler F., and Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behavior and neuropsychological function. J. Inherit. Metab. Dis. 9 (1986) 347-353
13. Krause W., Halminski M., McDonald L., Dembure P., Salvo R., Freides D., and Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria: a model for the study of phenylalanine and brain function in man. J. Clin. Invest. 75 (1985) 40-48
14. Burlina A.B., Bonafe L., Ferrari V., Suppiej A., Zacchello F., and Burlina A.P. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J. Inherit. Metab. Dis. 23 (2000) 313-316
15. Stahl S.M. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. second ed. (2000), Cambridge University Press, New York, NY
16. Weglage J., Rupp A., and Schmidt E. Personality characteristics in patients with phenylketonuria treated early. Pediatr. Res. 35 (1994) 611-613
17. Weglage J., Funders B., Ullrich K., Rupp A., and Schmidt E. Psychosocial aspects of phenylketonuria. Eur. J. Pediatr. 155 (1996) S101-S104
18. Weglage J., Grenzebach M., Pietsch M., Feldmann R., Linnenbank R., Denecke J., and Koch H.G. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and health controls. J. Inherit. Metab. Dis. 23 (2000) 487-496
19. Burgard P., Armbruster M., Schmidt E., and Rupp A. Psychopathology of patients treated early for phenylketonuria. Acta Paediatr. 407 (1994) 108-110
20. Pietz J., Fatkenheuer B., Burgard P., Armbruster M., Esser G., and Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics 99 (1997) 345-350
21. Antisdel J.E., and Chrisler J.C. Comparison of eating attitudes and behaviors among adolescents and young women with type 1 diabetes mellitus and phenylketonuria. J. Dev. Behav. Pediatr. 21 (2000) 81-86
22. Følling A. Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in Verbingdung mit Imbezillitat. Hoppe-Seylers Z. Physiol. Chem. 227 (1934) 169-176
23. Wood A.C., Friedmann C.J., and Steisel I.M. Psychological factors in phenylketonuria. Am. J. Orthopsychiatry 37 (1967) 671-679
24. Penrose L.S. The Biology of Mental Defect. fourth ed. (1972), Sidgwick & Jackson, London
25. Stevenson J.E., Hawcroft J., Lobascher M., Smith I., Wolff O.H., and Graham P.J. Behavioral deviance in children with early treated phenylketonuria. Arch. Dis. Child. 54 (1979) 14-18
26. Smith I., Beasley M.G., Wolff O.H., and Ades A.E. Behavior disturbance in 8-year-old children with early treated phenylketonuria. J. Pediatr. 112 (1988) 403-408
27. Smith I., and Beasley M.G. Intelligence and behaviour in children with early treated phenylketonuria. Eur. J. Clin. Nutr. 43 (1989) 1-5
28. Holtzman N., Kronmal R., van Doorninck W., Azen C., and Koch R. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. N. Engl. J. Med. 314 (1986) 593-598
29. Realmuto G.M., Garfinkel B.D., Tuchman M., Tsai M.Y., Chang P.N., Fisch R.O., and Shapiro S. Psychiatric diagnosis and behavioral characteristics of phenylketonuria children. J. Nerv. Ment. Dis. 174 (1986) 536-540
30. Arnold G.L., Vladutiu C.J., Orlowski C.C., Blakely E.M., and DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J. Inherit. Metab. Dis. 27 (2004) 137-143
31. Reber M., Kazak A.E., and Himmelberg P. Phenylalanine control and family functioning in early-treated phenylketonuria. J. Dev. Behav. Pediatr. 8 (1987) 311-317
32. Kazak A., Reber M., and Snitzer L. Childhood chronic disease and family functioning: a study of phenylketonuria. Pediatrics 81 (1988) 224-230
33. Matthews W.S., Barabas G., Cusack E., and Ferrari M. Social quotients of children with phenylketonuria before and after discontinuation of dietary therapy. Am. J. Ment. Defic. 91 (1986) 92-94
34. Weglage J., Funders B., Wilken B., Schubert D., Schmidt E., Burgard P., and Ullrich K. Psychological and social findings in adolescents with phenylketonuria. Eur. J. Pediatr. 151 (1992) 522-525
35. Sullivan J.E. Emotional outcome of adolescents and young adults with early and continuously treated phenylketonuria. J. Pediatr. Psychol. 26 (2001) 477-484
36. Landolt M.A., Nuoffer J.M., Steinmann B., and Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J. Pediatr. 140 (2002) 516-521
37. Ris M.D., Weber A.M., Hunt M.M., Berry H.K., Williams S.E., and Leslie N. Adult psychosocial outcome in early-treated phenylketonuria. J. Inherit. Metab. Dis. 20 (1997) 499-508
38. Ris M.D., Williams S.E., Hunt M.M., Berry H.K., and Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. J. Pediatr. 124 (1994) 388-392
39. Pietz J., Schmidt E., Matthis P., Kobialka B., Kuscha A., and de Sonneville L. EEGs in phenylketonuria. I. Follow-up to adulthood. II. Short-term diet-related changes in EEGs and cognitive function. Dev. Med. Child Neurol. 35 (1993) 54-64
40. Waisbren S.E., and Zaff J. Personality disorders in young women with treated phenylketonuria. J. Inherit. Metab. Dis. 17 (1994) 584-592
41. Koch R., Burton B., Hoganson G., Peterson R., Rhead W., Rouse B., Scott R., Wolff J., Stern A.M., Guttler F., Nelson M., de la Cruz F., Coldwell J., Erbe R., Geraghty M.T., Shear C., Thomas J., and Azen C. Phenylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis. 25 (2002) 333-346
42. Waisbren S.E., and Levy H.L. Agoraphobia in phenylketonuria. J. Inherit. Metab. Dis. 14 (1991) 755-764
43. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., and Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria. Health Qual. Life Outcomes 6 (2008) 25
44. Weglage J. Comments on behaviour in early treated phenylketonuria. Eur. J. Pediatr. 159 (2000) S94-S95
45. Anastasoaie V., Kurzius L., Forbes P., and Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 95 (2008) 17-20
46. Arnold G.L., Kramer B.M., Kirby R.S., Plumeau P.B., Blakely E.M., Sanger Cregan L.S., and Davidson P.W. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr. 87 (1998) 565-570
47. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B., and Sapropterin Study Group. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 154 (2009) 700-707
48. Diamond A., Ciaramitaro V., Donner E., Djali S., and Robinson M. An animal model of early-treated PKU. J. Neurosci. 14 (1994) 3072-3082